A cancer detection solution leads to rapid sales growth (FRA: PHS)

Get monthly updates

Receive monthly investment insights from our professional investment teams.

SUBSCRIBE NOW

Photocure (FRA: PHS), also known as The Bladder Cancer Company, develops products and services with the aim of improving the lives of bladder cancer patients. Among their stable of solutions is the liquid Cysview, which is injected into the bladder to increase the detection of bladder cancer during surgery and follow-up monitoring. Once the liquid is injected, cancerous cells glow red when illuminated with a purpose built blue light, allowing the cancer to be identified and surgically removed, reducing the likelihood of future recurrence.

Photocure has a current market capitalisation of USD $130m and we estimate  2018 revenue of USD $25m which is small compared to the potential US market opportunity valued at $1.3bn. The company has also had great success selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany.

Whilst penetration stands at only 2% in the USA the government’s recent announcement they would provide a rebate for the product has seen revenue growth accelerate from 36% year-on-year in the first quarter of 2018 to 56% year-on-year in the second. The accelerating sales growth, coupled with the company having no debt and low market value relative to its market opportunity, have positioned this stock as a favourite in the portfolio. We believe the company has a unique razor and razorblades model that will lead to a strong long-term defensible business model. This is due to the liquid and light source being approved together. The light source costs $80,000 each and most urologists will only purchase one lamp, making it difficult for a second player to enter the market.  The product also requires a high touch sales force offering training and support to urology clinics making generic entry into the market less likely.

We have chosen to invest in this stock for the following main reasons:

  1. Growth potential: the company has a comparatively small market capitalisation compared to the current market opportunity.
  2. International success: the company has already experienced success selling their product Cysview in Europe.
  3. The government rebate: The US government’s rebate announcement has resulted in rapid growth.
  4. New CEO with strong track record in growing medical device businesses in US market. We were able to take advantage of share price weakness to purchase shares at an attractive price.

This stock is currently held by our Pengana High Conviction Equities Fund

 


 

This report has been prepared by Pengana Capital Ltd (ABN 30 103 800 568, Australian Financial Services Licence No. 226566) (“Pengana”).  This report does not contain any investment recommendation or investment advice and has been prepared without taking account of any person’s objectives, financial situation or needs.  Therefore, before acting on the information in this report a person should consider the appropriateness of the information, having regard to their objectives, financial situation and needs.
Pengana is the issuer of units in the Pengana Emerging Companies Fund (ARSN 111 894 510) (“the Fund”).  A Product Disclosure Statement for the Fund (“PDS”) is available and can be obtained by contacting Pengana on (02) 8524 9900.  A person who is considering investing in the Fund should obtain the relevant PDS and should consider the PDS carefully and consult with their financial adviser to determine whether the Fund is appropriate for them before deciding whether to invest in, or to continue to hold, units in the Fund.
The value of investments can go up and down.  Past performance is not a reliable indicator of past performance.
While care has been taken in the preparation of this report, Pengana makes no representation or warranty as to the accuracy, currency or completeness of any statement, data or value.  To the maximum extent permitted by law, Pengana expressly disclaims any liability which may arise out of the provision to, or use by, any person of this report.

Get monthly insights and market commentary direct to your inbox

Pengana Capital Group